One comprehensive provider that does all doesn’t really exist. Individual segments have few competitors like Codi, Sabre, Amadeus that handle meta and Google. And as agencies like WPP and psPublicis that do social.
Posts in category Value Pickr
Kaveri seeds company limited — kscl (07-10-2023)
So I just did a quick research, Q1 is the summer season. Hence according to Google, almost half of the field crop seeds portfolio that Kaveri has is not suitable to grow in summers in India, hence summers may be more export-dependent. However, their vegetable portfolio has covered all major vegetables that grow in summer in India. This may be one reason for such skewed numbers.
NOT INVESTED, BUT LOOKING TO INVEST
Hitesh portfolio (07-10-2023)
Position sizing strategy remains as before. Anywhere from 6 to 10 stocks with starting allocations at around 10-15%. If position runs up due to sharp run ups, I allow it to run sometimes even to 30-35% of overall PF , but when I feel there is some chances of correction after sharp run up, I trim the position to bring it to comfort levels. If I find that the techno funda picture fits in perfectly and I have a clear idea about the company at the time of entry, I allocate high levels of 15-20% at entry levels itself, but these are rare instances.
This is a style and strategy that suits me as of now, so continuing with it.
TCS opportunity (07-10-2023)
TCS may announce buyback:
Expectation Rs 18,000-20,000 crore.
Offer Price: Rs 4300-4500
CMP: Rs 3620.20.
52-week high: Rs 3634.25
5th BB in 6 years
History of BB by TCS:
January 2022 – Rs 18,000 crore buyback at Rs 4500 per equity share.
December 2020 – Rs 16,000 crore buyback at Rs 3000 per equity share.
September 2018 – Rs 16,000 crore buyback at Rs 2100 per equity share.
May 2017 – Rs 16,000 crore buyback at Rs 2850 per equity share.
2017,2018 and 2020 has 100% acceptance ratio for retail whereas Jan 2022 was less.
Disc: Invested
Indostar Capital Finance Limited (07-10-2023)
Old but relevant if u are looking to study indostar and Used CV theme
52 week highs and all time highs strategy (07-10-2023)
Trident had an amazing run in 2021 when stock price went up from the levels of around 17 (marked in dotted blue horizontal line) in July 2021 when the above chart was discussed to a high of 70 in Jan 2022 ( 4 times in around 6 months) . Since then it went down along with other textile companies and posted a bottom at 25. This down move took nearly 14 months from Jan 2022 to March 2023. Since then it is attempting another upmove.
The beauty of the chart put below is its simplicity. Just two dotted blue sloping lines drawn to show breakout from falling trendline. In the latest upmove, stock price went up after breaking out above 37 to post a swing high of 43.75 and started correcting. Now after retest of breakout level of 37 (marked in solid green horizontal line) it is showing strength.
On candle sticks last week was a doji candle with a higher upper wick. This week it was a bull candle with a weekly low at 36.55 and closed at 38.50. The low for the week is very close to a previous major breakout level and at 61.8% retracement to entire previous rally.
Going ahead, levels of 36-37 are key support zones to be watched and key resistance at 42-43 levels. If and when resistances are taken out, we can see a good rally.
disc: I have taken a trading position at around current prices based on above technical picture with clear cut stop losses in mind. ( not a recommendation, please do your own diligence if you consider buying. )
VIVID GLOBAL IND Ltd – a small cap stock with consistently high RoE (07-10-2023)
I am not tracking this anymore. Had a quick look at screener after long time. Current growth parameters or charts do not look good as of now.
52 week highs and all time highs strategy (07-10-2023)
RACL on a daily TF.
After going registering an all time high last month, it was moving in channel (a downward flag like formation) and has shown good up-move in last 3 sessions followed with high volumes.
Multi-Disciplinary Reading – Book Reviews (07-10-2023)
Since people are discussing what and how to read more, I thought about sharing this book which I’m currently reading “How to Read a Book” by Mortimer J. Adler and Charles Van Doren.
It’s a great book which goes into details of:
- Various kinds of books
- Various ways to read a book
- Judging a book by the title and its contents
- Levels of Reading
and just everything related to how to become a better reader
Rainbow Children’s Medicare – Niche player in Hospital Industry (07-10-2023)
Hello friends,
Wanted to highlight below points on Rainbow Children’s Medicare –
-
Initially started in Hyderabad and achieved phenomenal success. Management was able to replicate their proven model in other cities – Bangalore and Chennai. Now, even Delhi is tracking well and that gave them the confidence to plan hub in Gurugram (Hub – 400 beds – 450cr greenfield capex)
-
Rainbow’s hidden moat is their doctor engagement model, children-friendly environment and robust tertiary level services. No competition w.r.t these factors and it is not easy for new entrant as children’s healthcare needs to be built very organically.
-
Any city with a 40-50 lakh population definitely requires min. 200 beds hospital to cater to critical care and specialties. Opportunity is huge, but it takes time to build it as children’s healthcare is organic.(In a way entry barrier)
-
Rainbow’s target base is critically ill children or complex problems where there is miniscule competition. Small children’s hospitals won’t be their competition. In fact they will refer to rainbow for complex cases.
-
None of these mother and child hospitals can actually build pediatric intensive care because this model is lot more complex and intensive care takes time to build. Rainbow has a very different play in this space.
-
Breakeven in children’s multispecialty at 30% occupancy (This is much better compared to general multispecialty).
-
Q2 and Q3 are generally peak season for pediatric business.
-
TAM to double at 14% cagr to 1,78,400cr by 2026
-
I believe Rainbow has best in class metrics compared to listed hospitals (capex per bed, ARPOB, ALOS etc). Eventually market might reward it with premium EV/EBITDA multiple.
Disclosure: Invested, and Not a Reco.